The U.S. Food and Drug Administration announced a request for information on October 5, 2026, seeking public feedback on early-phase clinical trial designs for ibogaine drug products.

552c7ae14

Psychedelics

Mind-altering substances like psilocybin, LSD, MDMA, and ayahuasca and their therapeutic and cultural use.

83 claims·1 news story

0